<DOC>
	<DOCNO>NCT00722384</DOCNO>
	<brief_summary>To establish tolerability preliminary efficacy Cand5 single intravitreal injection patient wet age-related macular degeneration .</brief_summary>
	<brief_title>Open Label Study Evaluation Tolerability Five Dose Levels Cand5</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Patients subfoveal predominantly classic , minimally classic purely occult lesion , secondary age relate macular degeneration , total lesion size ( include blood , atrophy/scar neovascularization ) &lt; 12 total disc area , least 50 % active CNV . Patients must visual acuity 20/50 20/320 study eye . Patients must better visual acuity fellow eye study eye . Subretinal hemorrhage ( ) must comprise 50 % total lesion size . Patients concomitant eye disease , include glaucoma , uveitis , diabetic retinopathy , presence pigment epithelial tear rip , acute ocular periocular infection study eye . Patients &gt; 3 prior PDT treatment Visudyne study eye . Patients receive PDT study eye within eight week prior baseline angiography/photography .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>AMD</keyword>
	<keyword>Macular Degeneration</keyword>
	<keyword>Opko Health</keyword>
	<keyword>Acuity Pharmaceuticals</keyword>
	<keyword>bevasiranib</keyword>
	<keyword>Cand5</keyword>
	<keyword>Age-Related</keyword>
</DOC>